leisure time -WSS

leisure time

author：Wikipedia 2025-08-12 11:28:16 - browse：1

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

WSS

Wegovy leads to weight loss. Can it treat depression, too?

Health Care Service Corp to buy Cigna Medicare Advantage plans

Doulas covered by Medicaid under New York's new plan

The SUPPORT Act is critical to fighting the opioid crisis

GSK to buy asthma

Zyn nicotine pouches become unlikely player in latest culture war

hotspot

leisure time

focus

United colonoscopy coverage change 'may cost lives,' doctors say

How generative AI ratchets up security threats for health systems

Continuity nursing helped my family in our darkest PICU moments

Medicare drug price negotiation legal challenge met with skepticism

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: The latest on Novavax, Merck, Bluebird

How to save PrEP access — and even expand it

Why you shouldn’t ask, “What country has the best health care?”

BioMarin wins approval for gene therapy to treat hemophilia A

Caregivers of transplant patients call for more support, training

Wikipedia

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Bernie Sanders is gearing up to subpoena pharma CEOs

HHS names first

Heart disease and mental health: A look at cardiac psychology

Health Care Service Corp to buy Cigna Medicare Advantage plans

entertainment

explore

hotspot

hotspot